New child cancer drug tests successful - Houston Business Journal:

Carrier XQB153D
The drug, AMD3100, was shown to reduce the growth of a tumo r by more than 75 percent in according to investigators who presented their findings Friday at the 22nd annualp meeting of the inSan “AMD3100 works by shuttinb down the process that tumors need to set up vasculat systems,” Patrick Zweidler-McKay, senior investigator on the said in a statement. “The drug doesn’t kill neuroblastomsa cells directly, but it prevents tumors from growinhg rapidly by disrupting theirblood “There is the possibilith that this therapy could help prevent neuroblastoma metastasias to the bone marrow. However, more studies are needed to investigate this theory.
” About 650 children in the Uniter States under the age of five are diagnosee each year with neuroblastoma, accordinbg to the . Of those children, nearly two-thirds are diagnosed after the cancee has metastasized to other partsx ofthe body. For these patients with high-riskj neuroblastoma, long-term survival is less than 40 percent becaused the tumors are often resistant totraditionapl chemotherapy.